NCT02844699 - A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Prostate Cancer

Interventions

DRUG

Mobilan (M-VM3)

Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.

DRUG

Placebo

5% infusion solution of dextrose (glucose)

Trial Locations (4)

Unknown

"Moscow State Budgetary Healthcare Institution City Clinical Hospital № 57 of Moscow Healthcare Department", Moscow

Moscow State University of Medicine and Dentistry, Moscow

"Federal State Budgetary Institution Saint Petersburg Clinical Scientific and Practical Center for Special types of medical care (Oncological)", Saint Petersburg

"Federal State Budgetary Institution Scientific Research Oncology Institute named after N.N. Petrov of the Ministry of Health of the Russian Federation", Saint Petersburg